Krystal Biotech Announces Positive Clinical Data for KB113 in Basal Cell Carcinoma Treatment for Gorlin Syndrome

Krystal Biotech reported positive initial proof-of-concept clinical data for KB113, an intratumoral immunotherapy, showing broad basal cell carcinoma regression in patients with Gorlin syndrome. Over 80% of assessed lesions regressed, with responses observed in both injected and non-injected lesions.